SUPERNUS PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $100.59 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-03-02
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $100.59M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $70.88M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $79.86M.
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $79.80M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $100.59M 10-K · filed 2026-03-02 |
| 2024-12-31 | $70.88M 10-K · filed 2025-02-25 |
| 2022-12-31 | $79.86M 10-K · filed 2023-03-09 |
| 2022-09-30 | $79.80M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $79.80M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $79.80M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $82.60M 10-K · filed 2022-04-13 |
| 2020-12-31 | $24.20M 10-K · filed 2021-03-08 |
| 2019-12-31 | $5.00M 10-K · filed 2020-02-28 |
| 2018-12-31 | $5.20M 10-K · filed 2019-03-01 |
| 2017-12-31 | $5.20M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |